The emergence of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable excitement within the healthcare community. This innovative dual GIP and GLP-1 receptor medication appears to offer notable improvements in body loss compared to existing therapies. Early research trials have shown significant declines in body fat percentage, possibly